A population‐based competing‐risks analysis of the survival of patients treated with radical cystectomy for bladder cancer

Patients treated with radical cystectomy represent a very heterogeneous group with respect to cancer‐specific and other‐cause mortality. Comorbidities and comorbidity‐associated events represent very important causes of mortality in those individuals. The authors examined the rates of cancer‐specific and other‐cause mortality in a population‐based radical cystectomy cohort.

[1]  Yair Lotan,et al.  Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. , 2006, The Journal of urology.

[2]  J. Hanley,et al.  Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. , 1999, JAMA.

[3]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[4]  B. Konety,et al.  Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. , 2003, The Journal of urology.

[5]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[6]  S. Boyd,et al.  Radical Cystectomy for Elderly Patients With Bladder Carcinoma. An Updated Experience With 404 Patients , 1999 .

[7]  D. Schottenfeld,et al.  The autopsy as a measure of accuracy of the death certificate. , 1982, Bulletin of the New York Academy of Medicine.

[8]  J. Montie.  Radical cystectomy in the elderly: comparison of survival between younger and older patients. , 2005, The Journal of urology.

[9]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[11]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[12]  Michael McCormack,et al.  A population based assessment of perioperative mortality after cystectomy for bladder cancer. , 2009, The Journal of urology.

[13]  B. Hollenbeck,et al.  Five‐year survival after surgical treatment for kidney cancer , 2007, Cancer.

[14]  A. Vickers,et al.  Age‐adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer , 2008, Cancer.

[15]  Y. Lotan,et al.  Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. , 2007, European urology.

[16]  S. Ramsey,et al.  Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. , 2011, Urologic oncology.

[17]  R. Sylvester,et al.  The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  G. Ergun,et al.  The prognostic significance of advanced age in patients with bladder cancer treated with radical cystectomy , 2009, BJU international.

[19]  J. Gore,et al.  Mortality increases when radical cystectomy is delayed more than 12 weeks , 2009, Cancer.

[20]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[21]  C. Vale.  Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis , 2003, The Lancet.

[22]  H. Miyake,et al.  Significance of radical cystectomy for bladder cancer in patients over 80 years old , 2006, International Urology and Nephrology.

[23]  Gerhard Jakse,et al.  The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. , 2009, European urology.